Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexamethasone controlled release - Taiwan Liposome Company

Next Previous
Drug Profile

Dexamethasone controlled release - Taiwan Liposome Company

Alternative Names: ProDex; TLC-399

Latest Information Update: 14 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiwan Liposome Company
  • Class Anti-inflammatories; Antiallergics; Antiemetics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Ketones; Non-opioid analgesics; Phosphates; Pregnadienetriols; Small molecules; Sodium compounds; Vestibular disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Retinal oedema

Most Recent Events

  • 04 Mar 2021 Phase I/II and phase II development are ongoing in Taiwan and USA (Taiwan Liposome Company pipeline, March 2021)
  • 31 Dec 2020 Taiwan Liposome Company has patent protection for dexamethasone controlled-release in Taiwan, USA, Canada, South Africa, Russia, New Zealand, South Korea, Japan, Hong Kong, China, Australia and in EU, prior to December 2020
  • 18 Dec 2020 Dexamethasone controlled release - Taiwan Liposome Company is available for licensing as of 18 Dec 2020. https://www.tlcbio.com/en-global

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top